Sugi Predict

Sugi Predict / Compounds / SCHEMBL16225686

SCHEMBL16225686

SCHEMBL16225686

OB(O)c1ccccc1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LIPG Q9Y5X9 1/20 0.50
▸ LIPE Q05469 1/20 0.48
▸ BCL2 P10415 1/20 0.48
▸ BCL2L1 Q07817 1/20 0.48
▸ CALM1 P0DP23 1/20 0.46
▸ HTR2A P28223 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ALOX5 P09917 1/20 0.42
▸ KEAP1 Q14145 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956554 1.00 LIPG (0.50) LIPGLIPEBCL2BCL2L1CALM1
SCHEMBL25625118 0.88 CA1 (0.45) LIPGLIPEBCL2BCL2L1KEAP1
SCHEMBL29116248 0.86 LIPG (0.46) LIPGLIPEKEAP1LMNAMEN1
SCHEMBL19616322 0.84 BCL2 (0.47) LIPEBCL2BCL2L1ALOX5
SCHEMBL29940325 0.83 LIPE (0.42) LIPGLIPEBCL2BCL2L1CALM1
SCHEMBL28796057 0.83 LIPE (0.42) LIPGLIPEBCL2BCL2L1CALM1
SCHEMBL5987891 0.81 LIPG (0.48) LIPGLMNAHPGDKMT2A
SCHEMBL29014484 0.81 LIPG (0.58) LIPGLIPEHTTKMT2A
SCHEMBL12989233 0.80 FOLH1 (0.50) KMT2AHIF1A
SCHEMBL31051099 0.77 BCL2 (0.44) LIPEBCL2BCL2L1CALM1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118515699-A Hirsutine alkaloid boric acid derivative and preparation method and application thereof 中国海洋大学 2024-08-20 — — CN disclosed
CN-116023209-A Synthesis method of intermediate and process for preparing bifonazole 重庆西南制药二厂有限责任公司 2023-04-28 — — CN disclosed
CN-111094295-B Novel compound and organic light emitting device comprising the same 株式会社LG化学 2022-05-17 — — CN disclosed
CN-108368107-B Fused heterocyclic compounds as S1P modulators 艾伯维公司 2021-11-26 — — CN disclosed
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITÉ DE STRASBOURG (FR) 2021-07-22 — — US disclosed
EP-3749305-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN Université de Strasbourg (FR) 2020-12-16 — — EP disclosed
CN-111683660-A Compounds and compositions for the treatment of pain 斯特拉斯堡大学 2020-09-18 — — CN disclosed
CN-111094295-A Novel compound and organic light emitting device comprising the same 株式会社LG化学 2020-05-01 — — CN disclosed
US-10556907-B2 Fused heterocyclic compounds as S1P modulators AbbVie Deutschland GmbH & Co. KG (DE) 2020-02-11 — — US disclosed
WO-2019149965-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITE DE STRASBOURG (FR) 2019-08-08 — — WO disclosed
US-10017501-B2 Benzimidazole derivatives as bromodomain inhibitors GILEAD SCIENCES, INC. (US) 2018-07-10 — — US disclosed
EP-3341369-A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS AbbVie Inc. (US) 2018-07-04 — — EP disclosed
WO-2017036978-A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS ABBVIE INC. (US) 2017-03-09 — — WO disclosed
US-20170057966-A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS AbbVie Deutschland GmbH & Co. KG (DE) 2017-03-02 — — US disclosed
US-20160376261-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. 2016-12-29 — — US disclosed
US-9458145-B2 Benzimidazole derivatives as bromodomain inhibitors GILEAD SCIENCES, INC. (US) 2016-10-04 — — US disclosed
US-20160075695-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. (US) 2016-03-17 — — US disclosed
EP-2994469-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS Gilead Sciences, Inc. (US) 2016-03-16 — — EP disclosed
US-20140336190-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. (US) 2014-11-13 — — US disclosed
WO-2014182929-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GILEAD SCIENCES, INC. (US) 2014-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN ACHE, TRPV1, OPRL1 LIPG 3981/4885LIPE 3396/4885BCL2 2593/4885
US-20170057966-A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS S1PR1, S1PR2, S1PR3 LIPG 66/4885LIPE 1071/4885BCL2 663/4885
US-10017501-B2 Benzimidazole derivatives as bromodomain inhibitors BRD4, BRD3, BRD1 LIPG 4325/4885LIPE 4245/4885BCL2 681/4885
US-20160075695-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 LIPG 4295/4885LIPE 4239/4885BCL2 640/4885
US-20160376261-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 LIPG 4325/4885LIPE 4245/4885BCL2 681/4885
US-20140336190-A1 BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 LIPG 4316/4885LIPE 4287/4885BCL2 665/4885
US-10556907-B2 Fused heterocyclic compounds as S1P modulators S1PR1, S1PR2, S1PR3 LIPG 66/4885LIPE 1071/4885BCL2 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.